Curriculum Vitae

PD Dr. med. Dr. nat. med. Deniz Hos

Deniz Hos

Department of Ophthalmology
University of Cologne
Kerpener Str. 62
50924 Cologne, GERMANY
Tel. (+49)-221-478 98896
Fax. (+49)-221-478 5094
Email: deniz.hos@uk-koeln.de

Scientific career

2002-2010 Medical School at the University of Erlangen-Nuremberg, Approbation (licence to practice medicine)

2006-2009 Study of Molecular Medicine at the University of Erlangen-Nuremberg, Diploma in Molecular Medicine

2006-2010 Doctorate degree (Dr. med) (summa cum laude) at the University of Erlangen-Nuremberg

2011- Resident physician and scientific assistant, Department of Ophthalmology, University Hospital of Cologne

2012-2016 PhD degree, Center for Molecular Medicine Cologne (CMMC), University of Cologne

2014-2019 Speaker, Young DOG (Residents of the German Ophthalmological Society)

2015- Principal Investigator of Project 5 “Myeloid cell function in corneal hem- and lymphangiogenesis” in the DFG Research Unit FOR 2240 “Angiogenesis, Lymphangiogenesis and Cellular Immunity in Inflammatory Diseases of the Eye” at the Department of Ophthalmology, University of Cologne

2016 European and German Board Exam in Ophthalmology

2017- Co-Principal Investigator, B3 “Novel therapeutic role of myeloid cell-derived VEGF-C and lymphangiogenesis in resolution of corneal inflammation and reestablishment of corneal transparency”, Center for Molecular Medicine Cologne (CMMC)

2018- Principal Investigator, CAP11 “The contribution of myeloid cells to corneal neovascular disease”, Career Advancement Group, Center for Molecular Medicine Cologne (CMMC)

2018- Principal Investigator of Project 5 “Myeloid cell function in corneal hem- and lymphangiogenesis” in the DFG Research Unit FOR 2240 “Angiogenesis, Lymphangiogenesis and Cellular Immunity in Inflammatory Diseases of the Eye” at the Department of Ophthalmology, University of Cologne

2019 Habilitation and Venia Legendi at the Medical Faculty, University of Cologne

Prizes and honors

2007 Travel grant, GlaxoSmithKline GmbH, ARVO Annual Meeting 2007, Fort Lauderdale, USA

2007 Research scholarship of the Interdisciplinary Center of Clinical Research, IZKF, University of Erlangen-Nuremberg

2010 Karl Giehrl Award 2011 for best medical dissertation, University of Erlangen-Nuremberg

2013 Dry Eye Research Award, Annual Meeting of the German Ophthalmological Society (DOG) 2013, Berlin, Germany

2014 Research Award of the German Ophthalmological Society (Eye foundation)

2017 Nomination “European Leadership Development Programme”, Class 2017-2019, European Society of Ophthalmology

2018 Helmholtz Research Award, German Ophthalmological Society

Selected publications

Hadrian K, Musial M, Schönberg A, Georgiev T, Küper C, Bock F, Jantsch J, Cursiefen C, Eming SA, Hos D (2022) The Role of the Osmosensitive Transcription Factor NFAT5 in Corneal Edema Resorption after Injury. Exp Mol Med. doi:10.1038/s12276-023-00954-w (2023)

Hadrian K, Willenborg S, Bock F, Cursiefen C, Eming SA, Hos D. (2021) Macrophage-Mediated Tissue Vascularization: Similarities and Differences Between Cornea and Skin. Front Immunol 12:667830. doi: 10.3389/fimmu.2021.667830.

Hos D, Matthaei M, Bock F, Maruyama K, Notara M, Clahsen T, Hou Y, Le VNH, Salabarria AC, Horstmann J, Bachmann BO, Cursiefen C. (2019) Immune reactions after modern lamellar DALK, DSAEK, DMEK) versus conventional penetrating corneal transplantation. Prog Retin Eye Res 73:100768.

Kiesewetter A, Cursiefen C, Eming SA, Hos D. (2019) Phase-specific functions of macrophages determine injury-mediated corneal hem- and lymphangiogenesis. Sci Rep. 9(1):308.

Hos D, Bukowiecki A, Horstmann J, Bock F, Bucher F, Heindl LM, Siebelmann S, Steven P, Dana R, Eming SA, Cursiefen C. (2017) Transient Ingrowth of Lymphatic Vessels into the Physiologically Avascular Cornea Regulates Corneal Edema and Transparency. Sci Rep. 7(1):7227

Hos NJ, Ganesan R, Gutierrez S, Hos D, Klimek J, Abdullah Z, Kronke M, Robinson N (2017) Type I interferon enhances necroptosis of Salmonella Typhimurium-infected macrophages by impairing antioxidative stress responses. The Journal of cell biology 216: 4107-4121.

Hos D, Bukowiecki A, Horstmann J, Bock F, Bucher F, Heindl LM, Siebelmann S, Steven P, Dana R, Eming SA, Cursiefen C (2017) Transient Ingrowth of Lymphatic Vessels into the Physiologically Avascular Cornea Regulates Corneal Edema and Transparency. Sci Rep. 3;7(1):7227.

Hos D, Tuac O, Schaub F, Stanzel TP, Schrittenlocher S, Hellmich M, Bachmann BO, Cursiefen C (2017) Incidence and Clinical Course of Immune Reactions after Descemet Membrane Endothelial Keratoplasty: Retrospective Analysis of 1000 Consecutive Eyes. Ophthalmology 124(4):512-518.

Cursiefen C, Bock F, Clahsen T, Regenfuss B, Reis A, Steven P, Heindl LM, Bosch JJ, Hos D, Eming S, Grajewski R, Heiligenhaus A, Fauser S, Austin J, Langmann T (2017) [New Therapeutic Approaches in Inflammatory Diseases of the Eye – Targeting Lymphangiogenesis and Cellular Immunity: Research Unit FOR 2240 Presents Itself]. Klinische Monatsblatter fur Augenheilkunde 234: 679-685.

Hos D, Bucher F, Regenfuss B, Dreisow ML, Bock F, Heindl LM, Eming SA, Cursiefen C (2016) IL-10 Indirectly Regulates Corneal Lymphangiogenesis and Resolution of Inflammation via Macrophages. Am J Pathol. 186(1):159-71.

Hos D, Dorrie J, Schaft N, Bock F, Notara M, Kruse FE, Krautwald S, Cursiefen C, Bachmann BO (2016) Blockade of CCR7 leads to decreased dendritic cell migration to draining lymph nodes and promotes graft survival in low-risk corneal transplantation. Experimental eye research 146: 1-6

Hos D, Schlereth SL, Bock F, Heindl LM, Cursiefen C (2015) Antilymphangiogenic therapy to promote transplant survival and to reduce cancer metastasis: what can we learn from the eye? Semin Cell Dev Biol. 38:117-30.

Lee HS, Hos D, Blanco T, Bock F, Reyes NJ, Mathew R, Cursiefen C, Dana R, Saban DR (2015) Involvement of corneal lymphangiogenesis in a mouse model of allergic eye disease. Invest Ophthalmol Vis Sci. 56(5):3140-8.

Hos D, Cursiefen C (2014) Lymphatic vessels in the development of tissue and organ rejection. Advances in anatomy, embryology, and cell biology 214: 119-41.

Hos D, Koch KR, Bucher F, Bock F, Cursiefen C, Heindl LM (2013) Serum eyedrops antagonize the anti(lymph)angiogenic effects of bevacizumab in vitro and in vivo. Investigative ophthalmology & visual science 54: 6133-42

Hos D, Regenfuss B, Bock F, Onderka J, Cursiefen C (2011). Blockade of insulin receptor substrate-1 inhibits corneal lymphangiogenesis. Invest Ophthalmol Vis Sci. 29;52(8):5778-85.

Hos D, Saban DR, Bock F, Regenfuss B, Onderka J, Masli S, Cursiefen C (2011) Suppression of inflammatory corneal lymphangiogenesis by application of topical corticosteroids. Arch Ophthalmol. 129(4):445-52.Cursiefen C, Bock F, Clahsen T,

Regenfuss B, Onderka J, Bock F, Hos D, Maruyama K, Cursiefen C (2010) Genetic heterogeneity of lymphangiogenesis in different mouse strains. Am J Pathol. 177(1):501-10.

Dietrich T, Bock F, Yuen D, Hos D, Bachmann BO, Zahn G, Wiegand S, Chen L, Cursiefen C (2010) Cutting edge: lymphatic vessels, not blood vessels, primarily mediate immune rejections after transplantation. J Immunol. 15;184(2):535-9.

Hos D, Bock F, Dietrich T, Onderka J, Kruse FE, Thierauch KH, Cursiefen C (2008) Inflammatory corneal (lymph)angiogenesis is blocked by VEGFR-tyrosine kinase inhibitor ZK 261991, resulting in improved graft survival after corneal transplantation. Investigative ophthalmology & visual science 49: 1836-42.

Hos D, Bachmann B, Bock F, Onderka J, Cursiefen C (2008) Age-related changes in murine limbal lymphatic vessels and corneal lymphangiogenesis. Experimental eye research 87: 427-32